Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 studyRichard Fox, Daniel H. Palmer, Hassan Malik et al.|The Lancet Oncology|2019Cited by 1.2k
Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary AdenocarcinomaJohn P. Neoptolemos, Fiona Campbell, Markus W. Büchler et al.|JAMA|2012Cited by 590
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trialGary Middleton, John P. Neoptolemos, Paul Silcocks et al.|The Lancet Oncology|2014Cited by 374
Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 TrialWilliam Greenhalf, Markus W. Büchler, Paula Ghaneh et al.|JNCI Journal of the National Cancer Institute|2013Cited by 333
First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic CancerSarah P. Blagden, Udai Banerji, Aurelius Olmin et al.|Clinical Cancer Research|2014Cited by 47